New drug targets tough cancers with KRAS G12D mutation
NCT ID NCT07417189
First seen Feb 20, 2026 · Last updated Jun 15, 2026 · Updated 16 times
Summary
This study tests an experimental drug called ABSK141 in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 401 adults with cancers like colorectal, lung, or pancreatic cancer are being recruited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, 201321, China
Contact
Conditions
Explore the condition pages connected to this study.